0000899140-19-000311.txt : 20190314 0000899140-19-000311.hdr.sgml : 20190314 20190313173308 ACCESSION NUMBER: 0000899140-19-000311 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20190314 DATE AS OF CHANGE: 20190313 GROUP MEMBERS: PAUL SEGAL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Alphatec Holdings, Inc. CENTRAL INDEX KEY: 0001350653 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 202463898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-82584 FILM NUMBER: 19679102 BUSINESS ADDRESS: STREET 1: 5818 EL CAMINO REAL CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 760-431-9286 MAIL ADDRESS: STREET 1: 5818 EL CAMINO REAL CITY: CARLSBAD STATE: CA ZIP: 92008 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: L-5 Healthcare Partners, LLC CENTRAL INDEX KEY: 0001733085 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 1700 BROADWAY STREET 2: 35TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 212-547-2914 MAIL ADDRESS: STREET 1: 1700 BROADWAY STREET 2: 35TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 SC 13D/A 1 l28554682.htm SCHEDULE 13D/A, #2

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Alphatec Holdings, Inc.
(Name of Issuer)
 
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
 
02081G102
(CUSIP Number)
 
Jeffrey Wade
c/o LS Power Development, LLC
1700 Broadway, 35th Floor
New York, New York 10019
212-547-2914
 
With a copy to:
Adam M. Turteltaub
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019
212-728-8129
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 
March 12, 2019
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this statement on Schedule 13D (this “Schedule 13D”), and is filing this Schedule 13D because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).







CUSIP No. 02081G102
Page 2 of  5 Pages

 
 
SCHEDULE 13D
   
 
1
 
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
L-5 Healthcare Partners, LLC
 
 
2
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) 
(b) 
 
 
3
 
SEC USE ONLY
 
 
 
4
 
SOURCE OF FUNDS
WC
 
 
5
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
 
 
6
 
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
 
7
 
SOLE VOTING POWER
0
 
 
8
 
SHARED VOTING POWER
14,682,540(1)
 
 
9
 
SOLE DISPOSITIVE POWER
0
 
 
10
 
SHARED DISPOSITIVE POWER
14,682,540(1)
 
 
11
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
14,682,540(1)
 
 
12
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
 
13
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
29.39% (2)
 
 
14
 
TYPE OF REPORTING PERSON
OO
 
 
(1)  Represents 7,936,508 shares of Common Stock held by L-5 Healthcare Partners, LLC, plus 6,746,032 shares of Common Stock issuable upon exercise of warrants to purchase shares of Common Stock at an exercise price of $3.50 per share (the “Warrants”), held by L-5 Healthcare Partners, LLC.
(2)  Calculation is based upon (i) 43,212,606 shares of Common Stock outstanding as reported in the Issuer’s Form 10-Q filed on November 9, 2018, plus (ii) the shares of Common Stock issuable upon exercise of the Warrants.





CUSIP No. 02081G102
Page 3 of  5 Pages

 
 
SCHEDULE 13D
 
1
 
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Paul Segal
 
2
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) 
(b) 
 
3
 
SEC USE ONLY
 
 
4
 
SOURCE OF FUNDS
OO
 
5
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
 
6
 
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
 
7
 
SOLE VOTING POWER
0
 
8
 
SHARED VOTING POWER
14,682,540(1)
 
9
 
SOLE DISPOSITIVE POWER
0
 
10
 
SHARED DISPOSITIVE POWER
14,682,540(1)
 
11
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
14,682,540(1)
 
12
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
 
13
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
29.39% (2)
 
14
 
TYPE OF REPORTING PERSON
IN
(1)  Represents 7,936,508 shares of Common Stock held by L-5 Healthcare Partners, LLC, plus 6,746,032 shares of Common Stock issuable upon exercise of warrants to purchase shares of Common Stock at an exercise price of $3.50 per share (the “Warrants”), held by L-5 Healthcare Partners, LLC.
(2)  Calculation is based upon (i) 43,212,606 shares of Common Stock outstanding as reported in the Issuer’s Form 10-Q filed on November 9, 2018, plus (ii) the shares of Common Stock issuable upon exercise of the Warrants.
 





CUSIP No. 02081G102
Page 4 of 5 Pages

The Schedule 13D filed with the Securities and Exchange Commission on March 16, 2018 (as previously amended, the "Schedule 13D") by (i) L-5 Healthcare Partners, LLC, a Delaware limited liability company (“L-5”), and (ii) Paul Segal, an individual with United States citizenship (collectively, the “Reporting Persons”), with respect to the common stock, par value $0.0001 per share (the “Common Stock”), of Alphatec Holdings, Inc., a Delaware corporation (the “Issuer”), is hereby amended to furnish the additional information set forth herein.  All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:
10b5-1 Plan
On March 12, 2019, L-5 Healthcare Partners II, LLC, an affiliate of L-5 and an entity controlled by Mr. Segal, entered into a purchase plan with J.P. Morgan Securities LLC (“JPMS”) in accordance with Rule 10b5-1 of the Securities and Exchange Act of 1934, as amended (the “10b5-1 Plan”) for the purchase of shares of Common Stock for an aggregate purchase price of up to $2,550,000 during the period beginning on March 26, 2019 and ending on September 30, 2019. Purchases are subject to Securities and Exchange Commission regulations, as well as to certain market price, volume and timing conditions specified in the 10b5-1 Plan. All purchases under the 10b5-1 Plan are to be made at the discretion of JPMS and in accordance with the terms, conditions and restrictions of the 10b5-1 Plan. None of L-5, any of its affiliates or Mr. Segal has any control, influence or authority over purchases made pursuant to the 10b5-1 Plan. The foregoing description of the 10b5-1 Plan is qualified in its entirety by reference to the 10b5-1 Plan, which is included as an Exhibit hereto and incorporated by reference.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Item 6 of the Schedule 13D is hereby amended and supplemented as follows:
The information set forth in Item 4 is incorporated by reference.
Item 7. Material to Be Filed as Exhibits.
Item 7 of the Schedule 13D is hereby supplemented as follows:
Exhibit 10.6    Purchase Plan, dated as of March 12, 2019, by and between L-5 Healthcare Partners II, LLC and J.P. Morgan Securities




CUSIP No. 02081G102
Page 5 of 5  Pages

SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Schedule 13D is true, complete and correct.

Dated:  March 13, 2019


 
L-5 HEALTHCARE PARTNERS, LLC
   
   
   
 
By: /s/ Paul Segal                              
 
Name: Paul Segal
 
Title: President
   
   
   
   
 
/s/ Paul Segal                              
 
Paul Segal


EX-10.6 2 l28554682b.htm PURCHASE PLAN
Exhibit 10.6

Purchase Plan


Purchase Plan, adopted March 12, 2019 (the “Purchase Plan, and such date the “Adoption Date”), between L-5 Healthcare Partners II, LLC (“Purchaser”) and J.P. Morgan Securities LLC (“JPMS”).  The purpose of this Purchase Plan is to aid in achieving the investment objectives of the Purchaser.

RECITALS

WHEREAS, the Purchaser desires to establish this Purchase Plan to buy common shares (the “Stock”) of Alphatec Holdings, Inc. (the “Issuer”);

WHEREAS, the Purchaser desires to buy a total number of shares of Stock with an aggregate purchase price (before deduction of standard and customary commissions and fees) of between $2,450,000 (the “Minimum Total Buying Limit”) and $2,550,000 (the “Maximum Total Buying Limit”) over the term of this Purchase Plan (all shares of Stock purchased pursuant to this Purchase Plan, the “Total Plan Shares”); and

WHEREAS, the Purchaser desires to engage JPMS to effect purchases of shares of Stock in accordance with the Purchase Plan;

NOW, THEREFORE, the Purchaser and JPMS hereby agree as follows:

A.  IMPLEMENTATION OF THE PURCHASE PLAN

1.  JPMS shall effect purchases (each a “Purchase”) of shares of Stock only on days on which the NASDAQ Global Select (the “Exchange”) is open and the Stock trades regular way on the Exchange (“Trading Day”), pursuant to the specific instructions specified on Schedule A.

2.  Purchaser acknowledges and agrees that JPMS will handle the above order on a best efforts basis.  In the event any limit prices of orders are away from the prevailing market at any time, there can be no assurance that such orders will be executed in whole or in part.  Purchaser agrees that all orders may be partially executed and will not be treated as an all or none order.

3.  In accordance with JPMS’s customary procedures, JPMS will deposit shares of Stock purchased hereunder into the JPMorgan Chase Bank, N.A. Asset Custody Account or JPMS Margin Brokerage Account (“Account”) of Purchaser against payment to JPMS of the purchase price therefor and commissions and other amounts in respect thereof payable pursuant to this Section.  Purchaser will be notified of all transactions pursuant to customary trade confirmations and will pay for such purchases within one standard settlement cycle after such purchase.  Purchaser’s obligation to make payment in respect of any shares of Stock purchased prior to any termination hereof shall survive such termination hereof.







4.  JPMS will charge its reasonable and customary commissions for the purchase of shares of Stock under this Purchase Plan, together with any other expenses incurred by JPMS in connection with such purchases.

5.  The Minimum Total Buying Limit, the Maximum Total Buying Limit, and the share amounts and prices, if applicable, set forth above and in Schedule A shall be adjusted automatically on a proportionate basis to take into account any stock split, reverse stock split or stock dividend with respect to the Stock or any change in capitalization with respect to the Issuer that occurs during the term of this Purchase Plan.

6.  Subject to Paragraph E.6, purchases will commence under this Purchase Plan on the Purchase Commencement Date, as defined in Schedule A, and shall terminate on the earlier of (a) the close of business on September 30, 2019; (b) the first date on which the aggregate price (before deduction of standard and customary commissions and fees) of the Total Plan Shares equals or exceeds the Minimum Total Buying Limit; (c) the date this Purchase Plan is terminated pursuant to Section D; (d) the dissolution or termination of Purchaser’s existence under applicable law, provided that any such dissolution or termination shall be made in good faith and not (i) for the purpose of indirectly causing termination of this Purchase Plan, (ii) as a part of a plan or scheme to evade the prohibitions of Rule 10b5-1 or other applicable securities laws, or (iii) as a part of a plan or scheme to evade the provisions of Section E of this Purchase Plan; (e) the date on which the unit of JPMS responsible for executing purchases of Stock pursuant to this Purchase Plan receives notice or otherwise becomes aware of (i) the closing of a tender or exchange offer with respect to the Stock or of a merger, acquisition, reorganization, recapitalization or comparable transaction affecting the securities of the Issuer as a result of which the Stock is to be exchanged or converted into shares of another company or for other consideration; or (ii) the commencement or impending commencement of any proceedings in respect of or triggered by Purchaser’s bankruptcy or insolvency; or (e) the failure of Purchaser to comply with Paragraph A.3 above. Notwithstanding the above, this Purchase Plan shall not be considered effective, but instead shall be considered null and void, if at least one of the accounts referenced in A.3 above has not been established in the name of Purchaser and open for the receipt of Stock by the Purchase Commencement Date. Purchaser understands that such an account cannot be opened until JPMS and its affiliates have performed customer due diligence and customer identification in accordance with internal policies and procedures and relevant federal laws including, but not limited to, the Bank Secrecy Act as amended by the USA PATRIOT Act and the regulations promulgated thereunder.  Purchaser understands that there may be significant time delays during this process and that an account may not be open for the receipt of Stock by the Purchase Commencement Date.

7.  Purchaser acknowledges and agrees that it (which for purposes of this Paragraph A.7 shall include both Purchaser itself and all persons acting on its behalf, which may include such Purchaser’s owners, managers and investment advisors, such persons collectively, “Purchaser Related Persons”) does not have authority, influence or control over any purchases of Stock effected by JPMS pursuant to this Purchase Plan, and will not attempt to exercise any authority, influence or control over such purchases.  JPMS agrees not to seek advice from Purchaser with respect to the manner in which it effects purchases under this Purchase Plan. JPMS may use its discretion in how to work the order to attempt to achieve the best execution below the maximum price per share, but at no time will the Purchaser communicate to JPMS any instructions on how to execute the order.







8.  Purchaser will be notified of all transactions pursuant to customary trade confirmations that are provided in the normal course of business. In addition, JPMS will use reasonable efforts notify both the Issuer and the Purchaser via email of each transaction pursuant to this Purchase Plan no later than one Trading Day after the trading date of such transaction.  Such notifications shall be sent to the following distribution list:

(i) Paul Segal (psegal@lspower.com); Darpan Kapadia (dkapadia@lspower.com); Jennifer Neill (jneill@lspower.com); Jeff Wade (jwade@lspower.com)

(ii) Craig Hunsaker (CHunsaker@atecspine.com); Tyson Marshall (TMarshall@atecspine.com)

or such other persons as Purchaser may direct in writing from time to time.

9.  Purchaser understands that JPMS may not be able to effect a purchase due to a market disruption or a legal, regulatory or contractual restriction or internal policy applicable to JPMS.  If any purchase cannot be executed as required by Paragraph A.1, due to a market disruption, a legal, regulatory or contractual restriction applicable to JPMS or any other such event, such purchase shall be cancelled and shall not be effected pursuant to this Purchase Plan, and, notwithstanding any language to the contrary herein, there shall be no carryover associated with such cancelled purchase.

10.  It is the intent of the parties that this Purchase Plan comply with the requirements of Rule 10b5-1(c)(1)(i)(B) and Rule 10b-18 under the Securities Exchange Act of 1934 (the “Exchange Act”) and this Purchase Plan shall be interpreted to comply with the requirements thereof.  JPMS shall comply with the requirements of paragraphs (b)(2), (b)(3) and (b)(4) of Rule 10b-18 under the Exchange Act in connection with Purchases of Stock in the open market pursuant to this Purchase Plan.  The Purchaser agrees not to take any action or cause another person to take any action that would cause Purchases not to comply with Rule 10b-18 or Rule 10b5-1.

B.  REPRESENTATIONS AND AGREEMENTS OF PURCHASER

1.  Purchaser (on behalf of itself and all Purchaser Related Persons) represents and warrants that as of the time of execution of, and entering into, this Purchase Plan, (a) to the best of Purchaser’s knowledge there is no blackout period (as defined in 17 C.F.R. Section 245.100(b), a “Blackout Period”) in effect for Issuer, (b) neither the Purchaser nor any person controlling the Purchaser (as such term is defined in Rule 405 under the Securities Act)  is aware of material, nonpublic information with respect to the Issuer or any securities of the Issuer (including the Stock) or of the actual or approximate beginning or ending dates of a Blackout period for Issuer, and (c) the Purchaser is entering into this Purchase Plan, and the transactions contemplated herein, in good faith and not as part of a plan or scheme to evade the prohibitions of any applicable laws or regulations, such as Rules 10b5-1 and 10b-18 under the Exchange Act.








2.  At the time of Purchaser’s execution of this Purchase Plan, neither Purchaser nor any Purchaser Related Person has entered into or altered a corresponding or hedging transaction with respect to the Total Plan Shares.  Purchaser agrees not to enter into any such transaction while this Purchase Plan remains in effect.

3.  Purchaser agrees to make all filings, if any, required under and monitor his own compliance with Sections 13(d), 13(g) and 16 of the Exchange Act.

4.  Purchaser acknowledges and agrees that JPMS has no duty to determine whether Purchaser has violated Sections 13(d), 13(g) or 16 of the Securities Exchange Act of 1934, as amended, or the rules adopted by the SEC thereunder, or any other laws or regulations applicable to the Purchaser in connection with this Purchase Plan.  Purchaser understands that this Plan in no way alters his obligations and responsibilities under Section 16, including those prohibitions against short swing profits.

5.  Purchaser understands the laws and regulations of U.S. states or non-United States jurisdictions (collectively, “State or Foreign Regulation”) may impose further restrictions or limitations on purchases of shares of Stock by or on behalf of Purchaser. State or Foreign Regulation may include, without limitation, the European Union Market Abuse Regulation (Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014). Purchaser acknowledges and agrees that JPMS has no duty to determine whether any State or Foreign Regulation would impose restrictions or limitations on this Purchase Plan. Purchaser understands that this Purchase Plan in no way alters his obligations and responsibilities, or the obligations and responsibilities of the Issuer, under State or Foreign Regulation. For the avoidance of doubt, references in this Purchase Plan to applicable laws, regulations and legal/regulatory restrictions shall be construed to include any applicable State and Foreign Regulation.

6.  Purchaser acknowledges and agrees that JPMS has not provided Purchaser with any tax, accounting or legal advice.  Purchaser understands that he should seek the advice of counsel regarding this Purchase Plan and the various securities and tax law issues related thereto.

7.  Purchaser agrees to notify JPMS promptly in the event of (a) trading restrictions being imposed as the result of any applicable regulatory prohibition or lock up event restricting purchases by or on behalf of affiliates, such as a stock offering or tender offer or (b) circumstances that would cause the purchases contemplated by this Purchase Plan not to qualify as “Rule 10b-18 purchases” as defined in Rule 10b-18(a)(13).







8.  Purchaser represents and warrants that it is able to purchase shares of Stock, as contemplated by this Purchase Plan, in accordance with the Issuer’s insider trading policies and Purchaser has obtained the acknowledgement of the Issuer that Purchaser has entered into this Purchase Plan.

C.  INDEMNIFICATION AND LIMITATION ON LIABILITY

1.  Purchaser agrees to indemnify and hold harmless JPMS and its directors, officers, employees and affiliates from and against all claims, losses, damages and liabilities (including without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or attributable to JPMS’s actions taken or not taken in compliance with this Purchase Plan or arising out of or attributable to any breach by Purchaser of this Purchase Plan (including Purchaser’s representations and warranties hereunder) or any violation by Purchaser of applicable laws or regulations.  This indemnification shall survive termination of this Purchase Plan.  Notwithstanding the foregoing, Purchaser shall have no indemnification obligation to the extent any claims, losses, damages or liabilities are due to the gross negligence, recklessness or willful misconduct of JPMS or any other indemnified person.

2.  Notwithstanding any other provision hereof, JPMS shall not be liable to Purchaser for: (a) special, indirect, punitive, exemplary or consequential damages, or incidental losses or damages of any kind, even if advised of the possibility of such losses or damages or if such losses or damages could have been reasonably foreseen; or (b) any failure to perform or to cease performance or any delay in performance that results from a cause or circumstance that is beyond its reasonable control, including but not limited to failure of electronic or mechanical equipment, strikes, failure of common carrier or utility systems, severe weather, market disruptions or other causes commonly known as “acts of God”.

D. SUSPENSION, TERMINATION AND AMENDMENT

1.  This Purchase Plan may be  terminated by Purchaser at any time upon one Trading Day prior written notice; provided however that JPMS may in its sole discretion decide to terminate on the same Trading Day that written notice is provided, if JPMS deems such action practicable.  Any such termination shall be made in good faith and not as a part of a plan or scheme to evade the prohibitions of Rule 10b5-1 or other applicable securities laws.  JPMS will require certain representations from Purchaser and acknowledgement of Issuer as a condition to such termination.

2.  This Purchase Plan shall be suspended, or at JPMS’s option, terminated, if JPMS receives notice, whether pursuant to Paragraph B.7 or otherwise, of (a) the occurrence of any legal, contractual or regulatory restriction applicable to Purchaser or its affiliates, including without limitation, any restriction related to a merger or acquisition, or (b) a stock offering requiring an affiliate lock-up, that would prohibit purchases pursuant to this Purchase Plan, or (c) if the Stock has been delisted from the Exchange, or becomes subject to the delisting procedure from the Exchange.








3.  Purchaser may amend or modify the economic trading parameters of this Purchase Plan (such as the number, size, price and timing of orders) only upon the written consent of JPMS.  Any such amendment or modification shall be made in good faith and not as a part of a plan or scheme to evade the prohibitions of Rule 10b5-1 or other applicable securities laws.  Purchaser agrees that it will not amend or modify this Purchase Plan at any time:  (a) that a Blackout Period is in effect for Issuer or (b) that it or any person controlling Purchaser (as such term is defined in Rule 405 under the Securities Act) is aware of any material non-public information about the Issuer and/or the Stock or of the actual or approximate beginning or ending dates of a Blackout Period for Issuer.  JPMS will require certain representations from Purchaser and acknowledgement of Issuer as a condition to such amendment or modification.

E.  GENERAL

1.  This Purchase Plan shall be governed by and construed in accordance with the laws of the State of New York without reference to choice of law principles. Except for modifications or amendments governed by Paragraph D.3, this Purchase Plan may be modified or amended only by a writing signed by the parties hereto and acknowledged by the Issuer.

2.  This Purchase Plan shall be subject to all terms and conditions governing the Purchaser’s Account, including the General Terms for Accounts and Services, the Asset Account Agreement and the JPMS Brokerage Agreement, including such provisions dealing with binding arbitration and waiving the right to litigate.  This Purchase Plan, together with the terms and conditions referenced in the preceding sentence, as well as any amendments or modifications made pursuant to this Purchase Plan and those terms and conditions, represent the complete agreement between the parties on these subjects.

3.  For the avoidance of doubt, to the extent this Purchase Plan requires Purchaser or any Purchaser Related Person to comply with the internal policies or procedures of the Issuer, Purchaser acknowledges and agrees that JPMS may rely solely on Purchaser’s execution of this Purchase Plan and has no duty to inquire independently as to Purchaser’s or any Purchaser Related Person’s compliance with such Issuer policies or procedures.

4.  All notices to JPMS under this Purchase Plan shall be given to JPMS by facsimile at (212) 464-1118 or by certified mail at J.P. Morgan Securities LLC, 270 Park Avenue, 5th Floor, New York, NY  10017, Attn:  Richelle Mackiewicz.

5.  Purchaser’s rights and obligations under this Purchase Plan may not be assigned or delegated without the written permission of JPMS.

6.  This Purchase Plan shall not be effective until executed by Purchaser and JPMS, and acknowledged by Issuer.  This Purchase Plan may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto were upon the same instrument.


[Signature page follows.]








Signature(s):
 
   
L-5 Healthcare Partners II, LLC
 
   
   
By:
/s/ Paul Segal                                           
March 12, 2019
 
Name:  Paul Segal
 
 
Title:    President
 
   
   
J.P. Morgan Securities LLC
 
   
By:
/s/ Richelle Mackiewicz                          
March 12, 2019
 
Name: Richelle Mackiewicz
 
 
Title:    Managing Director
 
   
   
Acknowledged:
 
Alphatec Holdings, Inc.
 
   
By:
/s/ Craig Hunsaker                                  
March 12, 2019
 
Name:  Craig Hunsaker
 
 
Title:    EVP & General Counsel
 
 
Address:  5818 El Camino Real,
                Carlsbad, CA 92008
 










GRAPHIC 3 image00001.jpg begin 644 image00001.jpg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

!O#=UX?\32BPN[.[E,?G A;B(D%7C/1P>>!R".0*J>!M.G\/^'?& M6OZS;W4,FO74TUO;+ [R[#O*9102"=QX/3C->PT4*&WD)U+W\SS7X 3F'X>V M&E75O=VU_9F7S8KBW>/ :1F!!8 '@CI7-7OB?P[IOQ1UZ\AUM?#U^A6UO%N; M=ITO=JC#A1C9CH#NY].>?;Z\W6PCO_$6MQ>.?#,-\@N2VG7BZ:)PUO@;5+(" MVX8.=V.M)Q:22*C).3;+G@:3P_-;:Y>>$M5M]6UJ\S/+K>@:.VCV,5G);2YC,(NG9E(Q&>0%"G)(&21C.,UZ'0HN2U!S47H M>$^&M4>+X!7>BS:7JJ7L=E<6>TV4GS32-)M11C)X()/09&3FKNCSM%^SE-I\ MMGJ"7XLYK'[,;.7S/-;<5&W;G!!!W=/>O::*:I^?2PG4\NMSAO@O<;OAYI-G M)!=6]U9PB&>*X@>)E;)_O 9&.